Aytu BioScience Revenue | AYTU

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue Aytu BioScience

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008	2007	2006	2005
66.4 M	65.2 M	107 M	96.7 M	65.6 M	27.6 M	7.32 M	3.66 M	3.22 M	2.56 M	262 K	58.9 K	1.75 K	1.75 K	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
107 M	1.75 K	31.9 M

Quarterly Revenue Aytu BioScience

2026-Q3	2026-Q2	2026-Q1	2025-Q4	2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
12.4 M	15.2 M	13.9 M	15.2 M	13.9 M	-	18.5 M	16.2 M	16.6 M	-	14 M	18.7 M	17.8 M	-	22.7 M	26.3 M	27.7 M	53.9 M	24.2 M	23.1 M	21.9 M	45 M	13.5 M	15.1 M	13.5 M	29 M	8.16 M	3.18 M	1.44 M	3.18 M	1.44 M	1.8 M	1.43 M	1.8 M	607 K	1.05 M	1.08 M	2.13 M	894 K	794 K	698 K	794 K	698 K	448 K	466 K	448 K	466 K	7 K	6 K	-	12.5 K	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
53.9 M	6 K	11.1 M

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
Фармсинтез LIFE	372 M	-	-	-	Russia
Aclaris Therapeutics ACRS	7.83 M	$ 5.64	5.92 %	$ 691 M	USA
Akebia Therapeutics AKBA	236 M	$ 0.99	4.33 %	$ 255 M	USA
Alector ALEC	21 M	$ 2.19	2.1 %	$ 226 M	USA
Aligos Therapeutics ALGS	2.19 M	$ 5.08	0.96 %	$ 50.2 M	USA
Alkermes plc ALKS	1.48 B	$ 45.83	0.22 %	$ 7.55 B	Irlanda
Allogene Therapeutics ALLO	22 K	$ 1.79	0.28 %	$ 395 M	USA
Alnylam Pharmaceuticals ALNY	3.71 B	$ 248.37	0.14 %	$ 32.5 B	USA
Altimmune ALT	41 K	$ 3.31	1.22 %	$ 292 M	USA
ALX Oncology Holdings ALXO	1.18 M	$ 1.93	0.52 %	$ 104 M	USA
Amgen AMGN	36.8 B	$ 380.17	0.75 %	$ 205 B	USA
Amphastar Pharmaceuticals AMPH	720 M	$ 23.96	0.74 %	$ 1.12 B	USA
Amarin Corporation plc AMRN	214 M	$ 14.02	1.59 %	$ 5.82 B	Irlanda
Amneal Pharmaceuticals AMRX	3.02 B	$ 17.23	1.29 %	$ 5.4 B	USA
AbbVie ABBV	16.6 B	$ 261.94	1.87 %	$ 463 B	USA
AnaptysBio ANAB	235 M	$ 54.77	1.67 %	$ 1.58 B	USA
Anika Therapeutics ANIK	113 M	$ 21.22	1.7 %	$ 304 M	USA
ANI Pharmaceuticals ANIP	883 M	$ 70.92	1.04 %	$ 1.42 B	USA
Aptevo Therapeutics APVO	3.11 M	$ 1.87	2.75 %	$ 590 K	USA
AbCellera Biologics ABCL	75.1 M	$ 11.04	1.38 %	$ 3.3 B	Canada
Aquestive Therapeutics AQST	44.5 M	$ 4.89	2.41 %	$ 523 M	USA
Arcturus Therapeutics Holdings ARCT	82 M	$ 15.23	3.39 %	$ 417 M	Israel
Ardelyx ARDX	407 M	$ 3.54	0.14 %	$ 853 M	USA
Armata Pharmaceuticals ARMP	823 K	$ 5.3	1.84 %	$ 192 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 24.35	1.95 %	$ 3.1 B	USA
Arvinas ARVN	263 M	$ 8.44	0.41 %	$ 598 M	USA
Arrowhead Pharmaceuticals ARWR	829 M	$ 80.24	0.11 %	$ 10.7 B	USA
Assembly Biosciences ASMB	72.3 M	$ 28.86	0.64 %	$ 324 M	USA
Actinium Pharmaceuticals ATNM	90 K	$ 1.25	6.87 %	$ 39 M	USA
Atara Biotherapeutics ATRA	121 M	$ 9.49	1.17 %	$ 119 M	USA
Agenus AGEN	114 M	$ 7.12	2.59 %	$ 212 M	USA
Aurinia Pharmaceuticals AUPH	77.1 M	$ 16.3	1.26 %	$ 2.19 B	Canada
Autolus Therapeutics plc AUTL	75.4 M	$ 1.94	2.93 %	$ 516 M	Britain
Atea Pharmaceuticals AVIR	351 M	$ 5.34	0.47 %	$ 435 M	USA
Axon Enterprise AXON	2.78 B	$ 491.2	2.47 %	$ 38.4 B	USA
Axsome Therapeutics AXSM	638 M	$ 216.73	0.75 %	$ 10.8 B	USA
BridgeBio Pharma BBIO	502 M	$ 72.33	0.1 %	$ 13.9 B	USA
BioCryst Pharmaceuticals BCRX	875 M	$ 8.2	0.92 %	$ 1.72 B	USA
Bicycle Therapeutics plc BCYC	72.6 M	$ 3.87	0.13 %	$ 268 M	Britain
Black Diamond Therapeutics BDTX	70 M	$ 2.03	2.52 %	$ 115 M	USA
Beam Therapeutics BEAM	140 M	$ 24.35	1.5 %	$ 2.41 B	USA
Biogen BIIB	9.89 B	$ 217.62	0.22 %	$ 31.9 B	USA
BioLineRx Ltd. BLRX	1.18 M	$ 2.48	0.2 %	$ 6.11 B	Israel
BioMarin Pharmaceutical BMRN	3.22 B	$ 66.22	0.82 %	$ 12.7 B	USA
Bristol-Myers Squibb Company BMY	48.2 B	$ 64.03	0.61 %	$ 130 B	USA
Benitec Biopharma BNTC	75 K	$ 12.11	0.08 %	$ 498 M	USA
Burford Capital Limited BUR	413 M	$ 4.35	1.13 %	$ 953 M	Britain